Merck Global Health Innovation Fund has made a strategic investment into Qure.ai as part of its Series D round.
My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.
Merck, Qure.ai collaborate to expand lung cancer detection via AI
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
NCI Director Anthony Letai announced the development of TrialMatch, an AI tool that helps oncologists identify clinical trials for their patients.
Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial.
UNC Lineberger Comprehensive Cancer Center has received $40 million from the OpenAI Foundation, the non-profit parent organization that governs the for-profit company OpenAI Group PBC, to generate data that could make personalized cancer vaccines more effective.
A rare inherited mutation in the Epidermal Growth Factor Receptor gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.
Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms—and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram—but there are still many significant limitations, according to a review led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
